A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00298688

Enrollment

Registered

2006-03-03

Start date

2004-09-30

Completion date

2007-03-31

Last updated

2008-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Brief summary

The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib

Interventions

DRUGGefitinib

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Provision of written informed consent * Histologically confirmed, relapsed or refractory SCLCr * Aged 18 or over and a life expectancy of more than 2 months

Exclusion criteria

* Any evidence of clinically active interstitial lung disease * Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.

Design outcomes

Primary

Measure	Time frame
To determine the disease control rate in these patients	—

Secondary

Measure	Time frame
To determine the objective response rate at trail closure in these patients	—
To determine the time to progression-or-death in these patients	—
To determine overall survival in these patients	—

Countries

Denmark, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026